申请人:AstraZeneca AB
公开号:US08859534B2
公开(公告)日:2014-10-14
The present invention relates to compounds of formula (I),
wherein
R1 is heteroaryl or heterocyclyl, optionally substituted;
R2 is C1-4alkyl, heterocyclyl, C1-4alkylaryl, C1-4alkylheteroaryl, carbocyclyl, C1-4alkylheterocyclyl, heterocyclyl-heteroaryl, aryl-heterocyclyl, carbocyclyl-heteroaryl, heterocyclyl-aryl, optionally substituted;
R3 is hydrogen or C1-4alkyl, or
R2 and R3 may together with the nitrogen atom, form a saturated ring system containing 4, 5 or 6 ring forming atoms, and optionally substituted;
R4 is hydrogen, halogen, methyl or methoxy;
to pharmaceutical composition containing said compounds and to the use of said compounds in therapy, for instance in treating cognitive disorders.
The present invention further relates to new intermediates useful in the preparation thereof.
本发明涉及公式(I)的化合物,其中R1是杂环芳基或杂环烷基,可选择性取代;R2是C1-4烷基,杂环基,C1-4烷基芳基,C1-4烷基杂环芳基,碳环基,C1-4烷基杂环基,杂环基-杂环芳基,芳基-杂环基,碳环基-杂环芳基,杂环基-芳基,可选择性取代;R3是氢或C1-4烷基,或R2和R3可以与氮原子一起形成含有4、5或6个环形成原子的饱和环系统,可选择性取代;R4是氢、卤素、甲基或甲氧基;以及含有该化合物的制药组合物以及该化合物在治疗中的使用,例如用于治疗认知障碍。本发明还涉及在其制备中有用的新中间体。